Search

Your search keyword '"Pemmaraju, A"' showing total 1,424 results
Start Over Author "Pemmaraju, A" Search Limiters Peer Reviewed
1,424 results on '"Pemmaraju, A"'

1. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms: MYELODYSPLASTIC NEOPLASM

Author

Bouligny, Ian M., Montalban-Bravo, Guillermo, Sasaki, Koji, Daver, Naval, Jabbour, Elias, Alvarado, Yesid, DiNardo, Courtney D., Ravandi, Farhad, Borthakur, Gautam, Pemmaraju, Naveen, Kadia, Tapan, Masarova, Lucia, Takahashi, Koichi, Andreeff, Michael, Bazinet, Alexandre, Yang, Hui, Kanagal, Rashmi, Pierce, Sherry, Meyer, Meghan, Huang, Xuelin, and Garcia-Manero, Guillermo

Published
2025
Full Text
View/download PDF

2. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Author

DiNardo, Courtney D., Verma, Divij, Baran, Natalia, Bhagat, Tushar D., Skwarska, Anna, Lodi, Alessia, Saxena, Kapil, Cai, Tianyu, Su, Xiaoping, Guerra, Veronica A., Poigaialwar, Gowri, Kuruvilla, Vinitha M., Konoplev, Sergej, Gordon-Mitchell, Shanisha, Pradhan, Kith, Aluri, Srinivas, Hackman, G. Lavender, Chaudhry, Sovira, Collins, Meghan, Sweeney, Shannon R., Busquets, Jonathan, Rathore, Atul Singh, Deng, Qing, Green, Michael R., Grant, Steven, Demo, Susan, Choudhary, Gaurav S., Sahu, Srabani, Agarwal, Beamon, Spodek, Mason, Thiruthuvanathan, Victor, Will, Britta, Steidl, Ulrich, Tippett, George D., Burger, Jan, Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Kadia, Tapan, Kornblau, Steven, Daver, Naval G., Naqvi, Kiran, Short, Nicholas J., Garcia-Manero, Guillermo, Tiziani, Stefano, Verma, Amit, and Konopleva, Marina

Published
2024
Full Text
View/download PDF

4. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis

Author

Urrutia, Samuel, Kantarjian, Hagop M., Ravandi-Kashani, Farhad, Bueso-Ramos, Carlos, Kanagal-Shamanna, Rashmi, Jabbour, Elias, Montalban-Bravo, Guillermo, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Dinardo, Courtney D., Kadia, Tapan M., Masarova, Lucia, Bose, Prithviraj, Pemmaraju, Naveen, Garcia-Manero, Guillermo, and Sasaki, Koji

Published
2024
Full Text
View/download PDF

5. Management of hemolytic transfusion reactions in a patient with chronic myelomonocytic leukemia and rare antibodies: A case report

Author

Grace S. Park, Himachandana Atluri, Courtney D. DiNardo, Bryan Guillroy, Jean Horak, Effrosyni Apostolidou, Maryam Buni, Guillermo Montalban Bravo, and Naveen Pemmaraju

Subjects
Hemolytic transfusion reactions, CMML, Induction therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Delayed hemolytic transfusion reaction (DHTR) poses a significant challenge in patients receiving blood transfusions. This case report highlights the complexities of managing DHTR in a newly diagnosed chronic myelomonocytic leukemia (CMML) patient with clinically significant JKa and little c antibodies during induction chemotherapy. A 46-year-old woman with CMML-2 who presented for induction chemotherapy was found to have hemolytic anemia. Due to presence of JKa and little c antibodies, she required intensive monitoring and supportive care measures. The coexistence of JKa and little c antibodies complicates transfusion management and chemotherapy tolerance in CMML patients.

Published
2025
Full Text
View/download PDF

6. Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms

Author

Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia, Nicholas J. Short, Hussein A. Abbas, Naszrin Arani, Courtney D. DiNardo, Gautam Borthakur, Naveen Pemmaraju, Betul Oran, Elizabeth Shpall, Uday Popat, Richard Champlin, Sherry Pierce, Sankalp Arora, Ghayas Issa, Musa Yilmaz, Keyur Patel, Koichi Takahashi, Guillermo Montalban-Bravo, Danielle Hammond, Fadi G. Haddad, Farhad Ravandi, Hagop M. Kantarjian, and Naval G. Daver

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospective analysis included patients with newly diagnosed MDS (>5% blasts) and AML with TP53 mutation(s) treated at MD Anderson Cancer Center. We factored patient age, TP53 aberration burden, therapy intensity and use of venetoclax in the AML subgroup, and allogeneic hematopoietic stem cell transplantation (HSCT) to interrogate outcomes. TP53 was annotated as high-risk (TP53HR) if >1 mutation, one mutation + allelic deletion or a single mutation with variant allele frequency (VAF) ≥40%; TP53 low risk (TP53LR) included a single TP53 mutation VAF

Published
2024
Full Text
View/download PDF

7. Unexpected Mediastinal Mass Etiology in B-Acute Lymphoblastic Leukemia

Author

Luan Phan, Elias Jabbour, Mara B. Antonoff, Nitin Jain, Pei Lin, Cesar Moran, and Naveen Pemmaraju

Subjects
mediastinal mass, b-acute lymphoblastic leukemia, schwannoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Immunologic diseases. Allergy, RC581-607
Abstract

Leukemic masses are a known complication in patients with hematologic malignancies. Here we present a case regarding a patient with recently diagnosed B-acute lymphoblastic leukemia (B-ALL) who presented with multiple sites of extramedullary involvement including an anterior mediastinal mass. This mass persisted despite multiple rounds of multiagent cytotoxic therapy. In this report, we summarize the literature regarding mediastinal masses in the setting of B-ALL and illustrate that such masses in patients with leukemias may have surprising etiology, separate from the primary disease.

Published
2024
Full Text
View/download PDF

8. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia

Author

Montalban-Bravo, Guillermo, Rodriguez-Sevilla, Juan Jose, Swanson, David Michael, Kanagal-Shamanna, Rashmi, Hammond, Danielle, Chien, Kelly, Sasaki, Koji, Jabbour, Elias, DiNardo, Courtney, Takahashi, Koichi, Short, Nicholas, Issa, Ghayas C., Pemmaraju, Naveen, Kadia, Tapan, Ravandi, Farhad, Daver, Naval, Borthakur, Gautam, Loghavi, Sanam, Pierce, Sherry, Bueso-Ramos, Carlos, Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2024
Full Text
View/download PDF

10. Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting

Author

Prajwal Dhakal, Mario Sy, Grerk Sutamtewagul, Eric Mou, Nanmeng Yu, and Naveen Pemmaraju

Subjects
blastic plasmacytic dendritic cell neoplasm, tagraxofusp-erzs, anticd123 targeted therapy, venetoclax, imgn632, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Immunologic diseases. Allergy, RC581-607
Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options. Currently, standard treatment strategies include clinical trials; chemotherapy regimens such as hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD); and tagraxofusp-erzs (TAG, previously SL-401) which is the first-in-class targeted therapy against CD123. TAG received Food and Drug Administration approval for frontline BPDCN treatment in December 2018 and has increasingly become an alternative to chemotherapy, offering potentially more effective and less toxic options. However, despite promising results, there are still patients who may be resistant to TAG monotherapy and/or who respond but eventually relapse. Herein, we discuss an important patient case of BPDCN treated with TAG and review BPDCN treatment strategies.

Published
2024
Full Text
View/download PDF

11. Intrapleural Fibrinolysis with Urokinase versus Alteplase in Complicated Pleural Effusions and Empyema: A Prospective Randomized Controlled Trial

Author

Sudipt Adhikari, Vikas Marwah, Robin Choudhary, Indermani Pandey, Tentu Ajai Kumar, Virender Malik, Arpita Pemmaraju, Shrinath Vasudevan, and Suraj Kapoor

Subjects
complicated pleural effusion, empyema, intrapleural fibrinolysis, urokinase, recombinant tissue plasminogen activator, alteplase, Diseases of the respiratory system, RC705-779
Abstract

Background Intrapleural fibrinolytic therapy (IPFT) has been used as an effective agent since 1949 for managing complicated pleural effusion and empyema. Several agents, such as streptokinase, urokinase (UK), and recombinant tissue plasminogen activator (rt-PA), have been found to be effective with variable effectiveness. However, a head-to-head controlled trial comparing the efficacy of the most frequently used agents, i.e., UK and rt-PA (alteplase) for managing complicated pleural effusion has rarely been reported. Methods A total of 50 patients were randomized in two intervention groups, i.e., UK and rt-PA. The dose of rt-PA was 10 mg, and that of UK was 1.0 lac units. UK was given thrice daily for 2 days, followed by clamping to allow the retainment of drugs in the pleural space for 2 hours. rt-PA was instilled into the pleural space twice daily for 2 days, and intercostal drainage was clamped for 1 hour. Results A total of 50 patients were enrolled into the study, of which 84% (n=42) were males and 16% (n=8) were females. Among them, 30 (60%) patients received UK, and 20 (40%) patients received alteplase as IPFT agents. The percentage of mean± standard deviation changes in pleural opacity was –33.0%±9.9% in the UK group and –41.0%±14.9% in the alteplase group, respectively (p=0.014). Pain was the most common adverse side effect, occurring in 60% (n=18) of the patients in the UK group and in 40% (n=8) of the patients in the alteplase group (p=0.24), while fever was the second most common side effect. Patients who reported early (within 6 weeks of onset of symptoms) showed a greater response than those who reported late for the intervention. Conclusion IPFT is a safe and effective option for managing complicated pleural effusion or empyema, and newer agents, such as alteplase, have greater efficacy and a similar adverse effect profile when compared with conventional agents, such as UK.

Published
2024
Full Text
View/download PDF

12. Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Author

Fiskus, Warren, Mill, Christopher P., Bose, Prithviraj, Masarova, Lucia, Pemmaraju, Naveen, Dunbar, Andrew, Birdwell, Christine E., Davis, John A., Das, Kaberi, Hou, Hanxi, Manshouri, Taghi, Jain, Antrix, Malovannaya, Anna, Philip, Kevin, Alhamadani, Noor, Matthews, Alicia, Lin, Katie, Flores, Lauren B., Loghavi, Sanam, DiNardo, Courtney, Su, Xiaoping, Rampal, Raajit K., and Bhalla, Kapil N.

Published
2025
Full Text
View/download PDF

15. Impact of viscous dissipation on MHD flow of Maxwell nanofluid across a linear stretching sheet

Author

Jithender Reddy Gurejala, Manideep Pampera, Raja Shekhar Pemmaraju, and Srinivasa Raju Rallabandi

Subjects
Nanofluid, Viscous dissipation, Maxwell fluid, Heat, QC251-338.5
Abstract

The viscous dissipation of Maxwell nanofluid movement on a stretching sheet is examined in the present article. Constructed the modelling equalities with assumptions and emerging parameters such as Magnetic parameters, thermophoresis, Brownian motion, and Biot number etc. Convert those equation to simple third-order ODEs by applying stream functions, MATHEMATICA software used to solve ODE by applying the RK method approach with shooting technique. Presented our outcomes graphically by incorporating the parameters. The elasticity of the Maxwell fluid is directly proportional to temperature, resulting in a reduction in its velocity. The factors that affect fluid flow include viscous dissipation, Lewis number, Brownian motion, and the reversibility of temperature and velocity. Increasing the parameters of Brownian motion leads to significant movement of the nanofluid particles, which in turn increases their kinetic energy and enhances heat generation in the boundary layer. The Lorentz force, which hinders the movement of fluid, leads to a decrease in velocity profiles. This is determined by the magnetic parameter. The heat transfer rate, the velocity decay rate, and the occurrence of viscous dissipation are all occurring in close proximity to the sheet. Also, the model tabular validation presented and current results align well with previously published studies. Cancer treatment and the cooling process in industries, polymer processing, biotechnology and medicine, food industry, cosmetics, oil and gas, textiles, aerospace and automotive, and construction are just a few of the technical and biological uses for it. Industries may enhance material performance, process efficiency, and product quality in a variety of applications by using Maxwell fluid models.

Published
2024
Full Text
View/download PDF

17. Proximate spin liquid and fractionalization in the triangular antiferromagnet KYbSe2

Author

Scheie, A. O., Ghioldi, E. A., Xing, J., Paddison, J. A. M., Sherman, N. E., Dupont, M., Sanjeewa, L. D., Lee, Sangyun, Woods, A. J., Abernathy, D., Pajerowski, D. M., Williams, T. J., Zhang, Shang-Shun, Manuel, L. O., Trumper, A. E., Pemmaraju, C. D., Sefat, A. S., Parker, D. S., Devereaux, T. P., Movshovich, R., Moore, J. E., Batista, C. D., and Tennant, D. A.

Published
2024
Full Text
View/download PDF

18. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

Author

Short, Nicholas J, Nguyen, Daniel, Jabbour, Elias, Senapati, Jayastu, Zeng, Zhihong, Issa, Ghayas C, Abbas, Hussein, Nasnas, Cedric, Qiao, Wei, Huang, Xuelin, Borthakur, Gautam, Chien, Kelly, Haddad, Fadi G, Pemmaraju, Naveen, Karrar, Omer S, Nguyen, Danielle, Konopleva, Marina, Kantarjian, Hagop, and Ravandi, Farhad

Published
2024
Full Text
View/download PDF

19. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients

Author

Naveen Pemmaraju, Branko Cuglievan, Joseph Lasky, Albert Kheradpour, Nobuko Hijiya, Anthony S. Stein, Soheil Meshinchi, Craig A. Mullen, Emanuele Angelucci, Luciana Vinti, Tariq I. Mughal, and Anna B. Pawlowska

Subjects
AYA BPDCN, CD123, pediatric BPDCN, plasmacytoid dendritic cells, tagraxofusp, Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10–20% of cases are pediatric or adolescent/young adult (AYA) patients. Tagraxofusp (TAG, Elzonris®) is the only approved treatment for BPDCN; in the United States it is approved for patients aged ≥2 years. Data on treating pediatric and AYA BPDCN patients are limited. We present a case series of pediatric and AYA patients with BPDCN treated with TAG. Eight patients (five newly diagnosed; three relapsed/refractory [R/R]), aged 2–21 years, received 12 mcg/kg TAG. Seven patients were female; most had skin (n = 6) and/or bone marrow (n = 4) involvement. No new safety signals were identified. Grade 3 adverse events were headache (n = 1) and transaminitis (n = 2). Three patients with newly diagnosed BPDCN achieved complete response, one achieved partial response, and one had stable disease (SD). One patient with R/R BPDCN achieved a minor response; one had SD. Seven patients (88%) were bridged to stem cell transplant: 80% of newly diagnosed patients and 100% of R/R patients. Five patients remained alive at last follow‐up. These cases highlight the efficacy and safety of TAG in pediatric and AYA patients for whom there is no other approved BPDCN therapy.

Published
2024
Full Text
View/download PDF

20. Spatially fractionated radiotherapy: Dosimetric and clinical report

Author

Shubhangi Barsing, Gopal Pemmaraju, Nagraj Huilgol, Anand Parab, and Anuradha Singh

Subjects
grid, lattice, valley, vertex, volumetric modulated arc treatment, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Aim: Lattice is a three-dimensional technical development of the two-dimensional grid technology, which forms high-dose “islands” amid a “sea” of lower dose. When compared to grid, lattice offers enhanced dose distribution and organs-at-risk (OAR) sparing, which may be useful for big or deep-seated cancers. In this study, we used a Halcyon 2.0 (6MV) linear accelerator to treat the palliative cases with lattice radiation using volumetric modulated arc treatment (VMAT). With new machines and techniques, it's becoming more difficult to adapt and reinvent traditional grid radiation. In our study, we used VMAT to deliver high-dose radiation to the tumor while sparing the surrounding areas and normal tissues. New methodologies and the same thing we showed in our study are bringing development to lattice planning. Materials and Methods: Four patients were treated with grid technique. All the structures of respective patients were manually contoured on Eclipse SomaVision for lattice planning, important parameters include the vertex volume diameter and center-to-center spacing. Spheres were contoured in the axial slice inside the gross tumor volume. VMAT was planned with a single isocenter and multiple arcs (full arcs 360°). Optimization was set giving high priorities to the target volume, ensuring that the tumor received the required dose and that the OARs were met. Results: VMAT lattice therapy as a strategy to improve initial responsiveness while reducing OAR toxicity. All the target spheres achieved >95% of the prescription dose and dose fall-off outside the target sphere was achieved due to the ring shape sphere constraints. Conclusions: Bulky tumors were treated with lattice radiation with a high dose per fraction in this study, with the vertices receiving the specified dose and the region between the vertices being spared. As it was a task for physicists to design a lattice radiation considering the vertices and periphery regions and to achieve the OARs according to the dose constraint protocol, the VMAT plan was well realized using optimization and computation.

Published
2024
Full Text
View/download PDF

21. Dedicated anticoagulation management protocols in fragility femoral fracture care – a source of significant variance and limited effectiveness in improving time to surgery: The hip and femoral fracture anticoagulation surgical timing evaluation (HASTE) study

Author

Smith, Matthew, Yoong, Andrel, Lim, Jun Wei, Yousef, Omar, McDonald, Stephen, Chileshe, Chinga, Ramus, Camilla, Clements, Christopher, Barrett, Liam, Rockall, Oliver, Geetala, Rahul, Islam, Saif Ul, Nasar, Ahmad, Almond, Kieran, Hassan, Ladan Fatima Yusuf, Shah, Sohan, Brand, Robert Bruce, Yawar, Bakhat, Gilmore, Catherine, McAuley, Daryl, Khan, Waleed, Subramanian, Padmanabhan, Ahluwalia, Aashish, Ozbek, Leyla, Awasthi, Prashant, Sheikh, Hassaan, Barkley, Sarah, Ardolino, Toni, Denning, Alexander, Thiruchandran, Gaj, Fraig, Hossam, Salim, Omar, Iqbal, Rabia, Guy, Stephen, Hogg, Jack, Bagshaw, Oliver, Asmar, Samir, Mitchell, Stephen, Quek, Fang, Fletcher, James, French, Jonathan, Graham, Selina, Sloper, Philip, Sadique, Hammad, Matera, Valentina, Sohail, Zain, Leong, Justin Wei, Issa, Fares, Greasley, Lauren, Marsden, Samuel, Parry, Lucy, Mannan, Syed, Zaheen, Humayoon, Moriarty, Peter, Manning, William, Morris, Timothy, Brockbanks, Carole, Ward, Peter, Pearce, Kim, McMenemy, Louise, Mahmoud, Mohamed, Kieffer, Will, Lal, Aayush, Collis, Justin, Chandrasekaran, Karthik, Foxall-Smith, Michael, Raad, Marjan, Kempshall, Peter, Cheuk, Jocelyn, Leckey, Sam, Gupta, Rishav, Engelke, Daniel, Kemp, Mark, Venkatesan, Aakaash, Hussain, Adnan, Simons, Michiel, Raghavendra, Ram Mohan, Rohra, Satish, Deo, Sunny, Vasarhelyi, Ferenc, Thelwall, Claire, Cullen, Krista, Al-Obaidi, Bilal, Fell, Adam, Thaumeen, Ahmad, Dadabhoy, Maria, Ali, Mira, Ijaz, Sameer, Lin, David, Khan, Basharat, Alsonbaty, Mohamed, Lebe, Moritz, Millan, Ravi Kant, Imam, Sam, Theobald, Emma, Cormack, Jonathan, Sharoff, Lokesh, Eardley, Will, Jeyapalan, Rathan, Alcock, Liam, Clayton, Julia, Bates, Natalie, Mahmoud, Yousif, Osborne, Alex, Ralhan, Shvaita, Carpenter, Catriona, Ahmad, Mahmood, Ravi, Sanjeev Musuvathy, Konbaz, Tarek, Lloyd, Thomas, Sheikh, Nomaan, Swealem, Ahmed, Soroya, Emma, Rayan, Faizal, Ward, Thomas, Vasireddy, Aswinkumar, Clarke, Ellisiv, Sikdar, Oishi, Smart, Yat Wing, Windley, Joseph, Ilagan, Belen, Brophy, Edel, Joseph, Sarah, Lowery, Kathryn, Jamjoom, Ammer, Ismayl, Ghiath, Aujla, Randeep, Sambhwani, Sharan, Ramasamy, Arul, Khalaf, Ahmed, Ponugoti, Nikhil, Teng, Wai Huang, Masud, Saqib, Otoibhili, Eghe, Clarkson, Martin, Nafea, Mohamed, Sarhan, Mohamed, Hanna, Shady, Kelly, Andrew, Curtis, Alex, Gourbault, Lysander, Tarhini, Mariam, Platt, Nicholas, Fleming, Thomas, Pemmaraju, Gopalakrishna, Choudri, Mohammed Junaid, Burahee, Abdus, Hassan, Labiba, Hamid, Laveeza, Loveday, David, Edres, Kareem, Schankat, Kerstin, Granger, Luke, Goodbun, Matthew, Parikh, Sunny, Johnson-Lynn, Sarah, Griffiths, Alexandra, Rai, Avinash, Chandler, Henry, Guiot, Luke, Appleyard, Thomas, Robinson, Karen, Fong, Angus, Watts, Anna, Stedman, Tobias, Walton, Victoria, Inman, Dominic, Liaw, Frank, Hadfield, James, McGovern, Julia, Baldock, Thomas, White, Jonathan, Seah, Matthew, Jacob, Neville, Ali, Zaid Haj, Goff, Thomas, Sanalla, Ahmed, Gomati, Ayoub, Nordin, Louise, Hassan, Eslam, Ramadan, Omar, Teoh, Kar Hao, Baskaran, Dinnish, Ngwayi, James, Abbakr, Lina, Blackmore, Noah, Mansukhani, Sameer, Guryel, Enis, Harper, Adam, Cashman, Emily, Brooker, Joanne, Pack, Louise, Regan, Nora, Wagner, Wilhelm, Selim, Amr, Archer, Debbie, McConaghie, Gregory, Patel, Ravi, Gibson, William, Pasapula, Chandra S, Youssef, Hesham, Aziz, Md Abdul, Subhash, Sadhin, Banaszkiewicz, Paul, Elzawahry, Ahmed, Neo, Chryssa, Wei, Nicholas, Bhaskaran, Arun, Sharma, Abhishek, Factor, Danielle, Shahin, Fatma, Shields, David, Ferreira, Catarina Dores Fernandes, Jeyakumar, Gowsikan, Liao, Quintin, Sinnerton, Robert, Ashwood, Neil, Sarhan, Islam, Ker, Andrew, Phelan, Sean, Paxton, James, McAuley, Joseph, Moulton, Lawrence, Mohamed, Ahmed, Dias, Ana, Ho, Beatrice, Francis, Daniel, Miller, Sarah, Phillips, Jon, Jones, Robin, Arthur, Calum, Oag, Erlend, Thutoetsile, Kamogelo, Bell, Katrina, Milne, Kirsty, Whitefield, Reiss, Patel, Kuntal, Singh, Abhimanyu, Morris, Geraint, Parkinson, Dawn, Patil, Amogh, Hamid, Hassan, Syam, Kevin, Singh, Rohit, Menon, Deepak, Crooks, Sophie, Borland, Steven, Rohman, Adam, Nicholson, Alys, Smith, Ben, Hafiz, Nauman, Kolhe, Shivam, Waites, Matthew, Piper, Dani, Westacott, David, Grimshaw, Jessica, Bott, Alasdair, Berry, Alexander, Battle, Joseph, Flannery, Oliver, Iyengar, Karthikeyan P, Thakur, Abdul Wadood, Yousef, Mina, Bansod, Vaibhav, El-nahas, Walaa, Dawe, Edward, Oladeji, Emmanuel, Federer, Simon, Trompeter, Alex, Pritchard, Anna, Shurovi, Badrun, Jordan, Chris, Little, Max, Sivaloganathan, Sivanshankar, Shaunak, Shalin, Watters, Hazel, Luck, Joshua, Zbaeda, Mohamed, Frasquet-Garcia, Antonio, Warner, Christian, Telford, Jeremy, Rooney, Joanna, Attwood, Joseph, Wilson, Faye, Panagiotopoulos, Andreas, Keane, Conal, Scott, Helen, Mazel, Rebecca, Maggs, Joanna, Skinner, Edward, McMunn, Finlay, Lau, Joshua, Ravikumar, Kasetti, Thakker, Dev, Gill, Moneet, McCarthy, Phillip, Fossey, Gavin, Shah, Sohaib, McAlinden, Gavan, McGoldrick, Peter, O'Brien, Scarlett, Patil, Sunit, Millington, Antonia, Umar, Hamza, Sehdev, Simran, Dyer-Hill, Thomas, Yu Kwan, Tsun, Tanagho, Andy, Hagnasir, Ahmed, White, Thomas, Bano, Christopher, Kissin, Eleanor, Ghani, Rafia, Thomas, Philip S W, McMullan, Mark, Walmsley, Matthew, Elgendy, Mohamed, Winstanley, Robert, Round, Joanne, Baxter, Mark, Thompson, Emett, Hogan, Kathryn, Youssef, Khaled, Fetouh, Sherif, Hopper, Graeme P, Simpson, Cameron, Warren, Craig, Waugh, Dominic, Nair, Gopikrishnan, Ballantyne, Andy, Blacklock, Calum, O'Connell, Ciara, Toland, Gemma, McIntyre, Joshua, Ross, Lauren, Badge, Ravindra, Loganathan, Deeraj, Turner, Ian, Ball, Matthew, Maqsood, Saad, Deierl, Krisztian, Beer, Alexander, Tan, Arthur Chen Wun, Mackinnon, Thomas, Gade, Venkat, Gill, James, Yu San, Kay, Archunan, Maheswaran Warren, Shaikh, Mariyam, Ugbah, Onyinye, Uwaoma, Sade, Pillai, Anand, Nath, Upamanyu, Rohan, Farhan-Alanie, M. M., Dixon, J., Irvine, S., Walker, R., and Eardley, W. G. P.

Published
2024
Full Text
View/download PDF

24. The impact of anticoagulant medications on fragility femur fracture care: The hip and femoral fracture anticoagulation surgical timing evaluation (HASTE) study

Author

Smith, Matthew, Yoong, Andrel, Lim, Jun Wei, Yousef, Omar, McDonald, Stephen, Chileshe, Chinga, Ramus, Camilla, Clements, Christopher, Barrett, Liam, Rockall, Oliver, Geetala, Rahul, Islam, Saif Ul, Nasar, Ahmad, Almond, Kieran, Hassan, Ladan Fatima Yusuf, Shah, Sohan, Brand, Robert Bruce, Yawar, Bakhat, Gilmore, Catherine, McAuley, Daryl, Khan, Waleed, Subramanian, Padmanabhan, Ahluwalia, Aashish, Ozbek, Leyla, Awasthi, Prashant, Sheikh, Hassaan, Barkley, Sarah, Ardolino, Toni, Denning, Alexander, Thiruchandran, Gaj, Fraig, Hossam, Salim, Omar, Iqbal, Rabia, Guy, Stephen, Hogg, Jack, Bagshaw, Oliver, Asmar, Samir, Mitchell, Stephen, Quek, Fang, Fletcher, James, French, Jonathan, Graham, Selina, Sloper, Philip, Sadique, Hammad, Matera, Valentina, Sohail, Zain, Leong, Justin Wei, Issa, Fares, Greasley, Lauren, Marsden, Samuel, Parry, Lucy, Mannan, Syed, Zaheen, Humayoon, Moriarty, Peter, Manning, William, Morris, Timothy, Brockbanks, Carole, Ward, Peter, Pearce, Kim, McMenemy, Louise, Mahmoud, Mohamed, Kieffer, Will, Lal, Aayush, Collis, Justin, Chandrasekaran, Karthik, Foxall-Smith, Michael, Raad, Marjan, Kempshall, Peter, Cheuk, Jocelyn, Leckey, Sam, Gupta, Rishav, Engelke, Daniel, Kemp, Mark, Venkatesan, Aakaash, Hussain, Adnan, Simons, Michiel, Raghavendra, Ram Mohan, Rohra, Satish, Deo, Sunny, Vasarhelyi, Ferenc, Thelwall, Claire, Cullen, Krista, Al-Obaidi, Bilal, Fell, Adam, Thaumeen, Ahmad, Dadabhoy, Maria, Ali, Mira, Ijaz, Sameer, Lin, David, Khan, Basharat, Alsonbaty, Mohamed, Lebe, Moritz, Millan, Ravi Kant, Imam, Sam, Theobald, Emma, Cormack, Jonathan, Sharoff, Lokesh, Eаrdley, Will, Jeyapalan, Rathan, Alcock, Liam, Clayton, Julia, Bates, Natalie, Mahmoud, Yousif, Osborne, Alex, Ralhan, Shvaita, Carpenter, Catriona, Ahmad, Mahmood, Ravi, Sanjeev Musuvathy, Konbaz, Tarek, Lloyd, Thomas, Sheikh, Nomaan, Swealem, Ahmed, Soroya, Emma, Rayan, Faizal, Ward, Thomas, Vasireddy, Aswinkumar, Clarke, Ellisiv, Sikdar, Oishi, Smart, Yat Wing, Windley, Joseph, Ilagan, Belen, Brophy, Edel, Joseph, Sarah, Lowery, Kathryn, Jamjoom, Ammer, Ismayl, Ghiath, Aujla, Randeep, Sambhwani, Sharan, Ramasamy, Arul, Khalaf, Ahmed, Ponugoti, Nikhil, Teng, Wai Huang, Masud, Saqib, Otoibhili, Eghe, Clarkson, Martin, Nafea, Mohamed, Sarhan, Mohamed, Hanna, Shady, Kelly, Andrew, Curtis, Alex, Gourbault, Lysander, Tarhini, Mariam, Platt, Nicholas, Fleming, Thomas, Pemmaraju, Gopalakrishna, Choudri, Mohammed Junaid, Burahee, Abdus, Hassan, Labiba, Hamid, Laveeza, Loveday, David, Edres, Kareem, Schankat, Kerstin, Granger, Luke, Goodbun, Matthew, Parikh, Sunny, Johnson-Lynn, Sarah, Griffiths, Alexandra, Rai, Avinash, Chandler, Henry, Guiot, Luke, Appleyard, Thomas, Robinson, Karen, Fong, Angus, Watts, Anna, Stedman, Tobias, Walton, Victoria, Inman, Dominic, Liaw, Frank, Hadfield, James, McGovern, Julia, Baldock, Thomas, White, Jonathan, Seah, Matthew, Jacob, Neville, Ali, Zaid Haj, Goff, Thomas, Sanalla, Ahmed, Gomati, Ayoub, Nordin, Louise, Hassan, Eslam, Ramadan, Omar, Teoh, Kar Hao, Baskaran, Dinnish, Ngwayi, James, Abbakr, Lina, Blackmore, Noah, Mansukhani, Sameer, Guryel, Enis, Harper, Adam, Cashman, Emily, Brooker, Joanne, Pack, Louise, Regan, Nora, Wagner, Wilhelm, Selim, Amr, Archer, Debbie, McConaghie, Gregory, Patel, Ravi, Gibson, William, Pasapula, Chandra S, Youssef, Hesham, Aziz, Md Abdul, Subhash, Sadhin, Banaszkiewicz, Paul, Elzawahry, Ahmed, Neo, Chryssa, Wei, Nicholas, Bhaskaran, Arun, Sharma, Abhishek, Factor, Danielle, Shahin, Fatma, Shields, David, Ferreira, Catarina Dores Fernandes, Jeyakumar, Gowsikan, Liao, Quintin, Sinnerton, Robert, Ashwood, Neil, Sarhan, Islam, Ker, Andrew, Phelan, Sean, Paxton, James, McAuley, Joseph, Moulton, Lawrence, Mohamed, Ahmed, Dias, Ana, Ho, Beatrice, Francis, Daniel, Miller, Sarah, Phillips, Jon, Jones, Robin, Arthur, Calum, Oag, Erlend, Thutoetsile, Kamogelo, Bell, Katrina, Milne, Kirsty, Whitefield, Reiss, Patel, Kuntal, Singh, Abhimanyu, Morris, Geraint, Parkinson, Dawn, Patil, Amogh, Hamid, Hassan, Syam, Kevin, Singh, Rohit, Menon, Deepak, Crooks, Sophie, Borland, Steven, Rohman, Adam, Nicholson, Alys, Smith, Ben, Hafiz, Nauman, Kolhe, Shivam, Waites, Matthew, Piper, Dani, Westacott, David, Grimshaw, Jessica, Bott, Alasdair, Berry, Alexander, Battle, Joseph, Flannery, Oliver, Iyengar, Karthikeyan P, Thakur, Abdul Wadood, Yousef, Mina, Bansod, Vaibhav, El-nahas, Walaa, Dawe, Edward, Oladeji, Emmanuel, Federer, Simon, Trompeter, Alex, Pritchard, Anna, Shurovi, Badrun, Jordan, Chris, Little, Max, Sivaloganathan, Sivanshankar, Shaunak, Shalin, Watters, Hazel, Luck, Joshua, Zbaeda, Mohamed, Frasquet-Garcia, Antonio, Warner, Christian, Telford, Jeremy, Rooney, Joanna, Attwood, Joseph, Wilson, Faye, Panagiotopoulos, Andreas, Keane, Conal, Scott, Helen, Mazel, Rebecca, Maggs, Joanna, Skinner, Edward, McMunn, Finlay, Lau, Joshua, Ravikumar, Kasetti, Thakker, Dev, Gill, Moneet, McCarthy, Phillip, Fossey, Gavin, Shah, Sohaib, McAlinden, Gavan, McGoldrick, Peter, O'Brien, Scarlett, Patil, Sunit, Millington, Antonia, Umar, Hamza, Sehdev, Simran, Dyer-Hill, Thomas, Yu Kwan, Tsun, Tanagho, Andy, Hagnasir, Ahmed, White, Thomas, Bano, Christopher, Kissin, Eleanor, Ghani, Rafia, Thomas, Philip S W, McMullan, Mark, Walmsley, Matthew, Elgendy, Mohamed, Winstanley, Robert, Round, Joanne, Baxter, Mark, Thompson, Emett, Hogan, Kathryn, Youssef, Khaled, Fetouh, Sherif, Hopper, Graeme P, Simpson, Cameron, Warren, Craig, Waugh, Dominic, Nair, Gopikrishnan, Ballantyne, Andy, Blacklock, Calum, O'Connell, Ciara, Toland, Gemma, McIntyre, Joshua, Ross, Lauren, Badge, Ravindra, Loganathan, Deeraj, Turner, Ian, Ball, Matthew, Maqsood, Saad, Deierl, Krisztian, Beer, Alexander, Tan, Arthur Chen Wun, Mackinnon, Thomas, Gade, Venkat, Gill, James, Yu San, Kay, Archunan, Maheswaran Warren, Shaikh, Mariyam, Ugbah, Onyinye, Uwaoma, Sade, Pillai, Anand, Nath, Upamanyu, Rohan, Farhan-Alanie, M.M., Chinweze, R., Walker, R., and Eardley, W.G.P.

Published
2024
Full Text
View/download PDF

27. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Author

Daver, Naval G, Montesinos, Pau, DeAngelo, Daniel J, Wang, Eunice S, Papadantonakis, Nikolaos, Todisco, Elisabetta, Sweet, Kendra L, Pemmaraju, Naveen, Lane, Andrew A, Torres-Miñana, Laura, Thompson, James E, Konopleva, Marina Y, Sloss, Callum M, Watkins, Krystal, Bedse, Gaurav, Du, Yining, Malcolm, Kara E, Zweidler-McKay, Patrick A, and Kantarjian, Hagop M

Published
2024
Full Text
View/download PDF

29. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Author

Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, and Courtney D. DiNardo

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2023
Full Text
View/download PDF

30. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Author

Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Sharon D. Bledsoe, Naval G. Daver, Elias J. Jabbour, Tapan M. Kadia, Zeev Estrov, Steven M. Kornblau, Michael Andreeff, Nitin Jain, Jorge E. Cortes, Gautam Borthakur, Yesid Alvarado, Mary Ann Richie, Mackenzie H. Dobbins, Selene A. McCrackin, Lingsha Zhou, Sherry A. Pierce, Xuemei Wang, Allison M. Pike, Guillermo Garcia-Manero, Hagop M. Kantarjian, and Srdan Verstovsek

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2024
Full Text
View/download PDF

31. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

Author

Senapati, Jayastu, Muftuoglu, Muharrem, Ishizawa, Jo, Abbas, Hussein A., Loghavi, Sanam, Borthakur, Gautam, Yilmaz, Musa, Issa, Ghayas C., Dara, Samuel I., Basyal, Mahesh, Li, Li, Naqvi, Kiran, Pourebrahim, Rasoul, Jabbour, Elias J., Kornblau, Steven M., Short, Nicholas J., Pemmaraju, Naveen, Garcia-Manero, Guillermo, Ravandi, Farhad, Khoury, Joseph, Daver, Naval, Kantarjian, Hagop M., Andreeff, Michael, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

32. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Author

Short, Nicholas J., Jabbour, Elias, Jain, Nitin, Senapati, Jayastu, Nasr, Lewis, Haddad, Fadi G., Li, Zhenhua, Hsiao, Yu-Chih, Yang, Jun J., Pemmaraju, Naveen, Ohanian, Maro, Wierda, William G., Montalban-Bravo, Guillermo, Borthakur, Gautam, Han, Lina, Xiao, Lianchun, Huang, Xuelin, Abramova, Regina, Zhao, Min, Garris, Rebecca, Konopleva, Marina, Ravandi, Farhad, and Kantarjian, Hagop

Published
2024
Full Text
View/download PDF

33. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Author

Bataller, Alex, Bazinet, Alexandre, DiNardo, Courtney D., Maiti, Abhishek, Borthakur, Gautam, Daver, Naval G., Short, Nicholas J., Jabbour, Elias J., Issa, Ghayas C., Pemmaraju, Naveen, Yilmaz, Musa, Montalban-Bravo, Guillermo, Takahashi, Koichi, Loghavi, Sanam, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop M., and Kadia, Tapan M.

Published
2024
Full Text
View/download PDF

34. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Author

Lane, Andrew A., Garcia, Jacqueline S., Raulston, Evangeline G., Garzon, Jada L., Galinsky, Ilene, Baxter, Emilie W., Leonard, Rebecca, DeAngelo, Daniel J., Luskin, Marlise R., Reilly, Christopher R., Stahl, Maximilian, Stone, Richard M., Vedula, Rahul S., Wadleigh, Martha M., Winer, Eric S., Mughal, Tariq, Brooks, Christopher, Gupta, Ira V., Stevenson, Kristen E., Neuberg, Donna S., Ren, Siyang, Keating, Julia, Konopleva, Marina, Stein, Anthony, and Pemmaraju, Naveen

Published
2024
Full Text
View/download PDF

35. Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Author

Sasaki, Koji, Garcia-Manero, Guillermo, Nigo, Masayuki, Jabbour, Elias, Ravandi, Farhad, Wierda, William G., Jain, Nitin, Takahashi, Koichi, Montalban-Bravo, Guillermo, Daver, Naval G., Thompson, Philip A., Pemmaraju, Naveen, Kontoyiannis, Dimitrios P., Sato, Junya, Karimaghaei, Sam, Soltysiak, Kelly A., Raad, Issam I., Kantarjian, Hagop M., and Carter, Brett W.

Published
2024
Full Text
View/download PDF

36. Gastrointestinal Manifestations and Liver Abnormalities in COVID-19: A Real-World Experience and a Novel COVID-19 Prognostic Index

Author

Manish Manrai, Vikas Marwah, Deepu Peter, Vishal Mangal, P Harikrishnan, Yogendra Mishra, Manish Sharma, and Arpitha Pemmaraju

Subjects
aspartate aminotransferase, coronavirus disease-2019, liver function tests, lactate dehydrogenase, severe acute respiratory syndrome coronavirus 2, Medicine
Abstract

Introduction: Gastrointestinal (GI) manifestations and liver function abnormalities have been reported in Coronavirus Disease-2019 (COVID-19). However, data is variable and lacking from the Indian Population. Moreover, the prognostic implication of these manifestations has not been well-defined Aim: To determine the impact of COVID-19, on the gastrointestinal tract and Liver Function Test (LFT) and develop a prognostic model for mortality Materials and Methods: An observational descriptive study was conducted in the Department of Internal Medicine at a temporary dedicated COVID-19 centre in a Tertiary Care Cardiothoracic Centre, Western Maharashtra, India. The hospital records of all the patients admitted from July 2020 to September 2020 were analysed. Clinical details and laboratory details were obtained from 589 Reverse Transcription– Polymerase Chain Reaction (RT-PCR) confirmed patients. The data was analysed and a prognostic scoring system was developed. Patients with positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RT-PCR on nasopharyngeal or oropharyngeal swabs. The data was entered in Microsoft Excel 2010 worksheet and t-test or Mann-Whitney test was also applied to compare the mean of variables being studied by separation of living and deceased patients based on the normality of the quantitative data. Results: The mean age±SD of the study participants was 44.74±19.61 years. The majority {127/589 (21.56 %)} of the patients were in the age group of 51-60 years. A total of 5 (0.84%) out of 589 patients had diarrhoea, and 3 (0.51%) had vomiting at the time of admission. Elevated Aspartate Aminotransferase (AST), Alanine Transaminase (AST), Alkaline Phosphatase (ALP), Gamma-glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatine Kinase Myocardial Band (CK-MB) was reported in non survivors in 45 (90%), 39 (78%), 15 (30%), 28 (56%), 48 (96%) and 49 (98%) out of 50 cases, respectively. The prognostic scoring system was developed with the following variables: age, Diabetes Mellitus (DM), symptomatic, breathlessness, albumin, AST, ALP, LDH, Prothrombin Time (PT), D-Dimer. The area under the curve, came out to be 0.91 and a cut-off value of three in the scoring system was able to predict death at a sensitivity of 85.5% and specificity of 79.6%. Conclusion: Gastrointestinal manifestations and abnormalities in LFTs are important extrapulmonary manifestations of COVID19. Patients with abnormal liver tests had higher risks of progressing to severe disease. Hence, LFT should be monitored and evaluated frequently during hospitalisation for COVID-19.

Published
2023
Full Text
View/download PDF

37. Lack of regional pathways impact on surgical delay: Analysis of the Orthopaedic Trauma Hospital Outcomes–Patient Operative Delays (ORTHOPOD) study

Author

Stevenson, Iain, Yoong, Andrel, Rankin, Iain, Dixon, James, Lim, Jun Wei, Sattar, Mariam, McDonald, Stephen, Scott, Sharon, Davies, Helen, Jones, Louise, Nolan, Michelle, McGinty, Rebecca, Stevenson, Helene, Bowe, David, Sim, Francis, Vun, James, Strain, Ritchie, Giannoudis, Vasileios, Talbot, Christopher, Gunn, Christopher, Le, Ha Phuong Do, Bradley, Matthew, Lloyd, William, Hanratty, Brian, Lim, Yizhe, Brookes-Fazakerley, Steven, Varasteh, Amir, Francis, Jonathan, Choudhry, Nameer, Malik, Sheraz, Vats, Amit, Evans, Ashish, Garner, Madeleine, King, Stratton, Zbaeda, Mohamed, Diamond, Owen, Baker, Gavin, Napier, Richard, Guy, Stephen, McCauley, Gordon, King, Samuel, Edwards, Gray, Lin, Benjamin, Davoudi, Kaveh, Haines, Samuel, Raghuvanshi, Manav, Buddhdev, Pranai, Karam, Edward, Nimmyel, Enoch, Ekanem, George, Lateef, Razaq, Jayadeep, JS, Crowther, Ian, Mazur, Karolina, Hafiz, Nauman, Khan, Umair, Chettiar, Krissen, Ibrahim, Amr, Gopal, Prasanth, Tse, Shannon, Lakshmipathy, Raj, Towse, Claudia, Al-Musawi, Hashim, Walmsley, Matthew, Aspinall, Will, Metcalfe, James, Moosa, Aliabbas, Crome, George, Abdelmonem, Mohamed, Lakpriya, Sathya, Hawkins, Amanda, Waugh, Dominic, Kennedy, Matthew, Elsagheir, Mohamed, Kieffer, Will, Oyekan, Adekinte, Collis, Justin, Raad, Marjan, Raut, Pramin, Baker, Markus, Gorvett, Alexander, Gleeson, Hannah, Fahmy, John, Walters, Sam, Tinning, Craig, Chaturvedi, Abhishek, Russell, Heather, Alsawada, Osama, Sinnerton, Robert, Crane, Evan, Warwick, Catherine, Dimascio, Lucia, Ha, Taegyeong Tina, King, Thomas, Engelke, Daniel, Chan, Matthew, Gopireddy, Rajesh, Deo, Sunny, Vasarhelyi, Ferenc, Jhaj, Jasmeet, Dogramatzis, Kostas, McCartney, Sarah, Ardolino, Toni, Fraig, Hossam, Hiller-Smith, Ryan, Haughton, Benjamin, Greenwood, Heather, Stephenson, Nicola, Chong, Yuki, Sleat, Graham, Saedi, Farid, Gouda, Joe, Ravi, Sanjeev Musuvathy, Henari, Shwan, Imam, Sam, Howell, Charles, Theobald, Emma, Wright, Jan, Cormack, Jonathan, Borja, Karlou, Wood, Sandy, Khatri, Amulya, Bretherton, Chris, Tunstall, Charlotte, Lowery, Kathryn, Holmes, Benjamin, Nichols, Jennifer, Bashabayev, Beibit, Wildin, Clare, Sofat, Rajesh, Thiagarajan, Aarthi, Abdelghafour, Karim, Nicholl, James, Abdulhameed, Ahmed, Duke, Kathryn, Maling, Lucy, McCann, Matthew, Masud, Saqib, Marshman, James, Moreau, Joshua, Cheema, Kanwalnaini, Rageeb, Peter Morad, Mirza, Yusuf, Kelly, Andrew, Hassan, Abdul, Christie, Alexander, Davies, Angharad, Tang, Cary, Frostick, Rhiannon, Pemmaraju, Gopalakrishna, Handford, Charles, Chauhan, Govind, Dong, Huan, Choudri, Mohammed Junaid, Loveday, David, Bawa, Akshdeep, Baldwick, Cheryl, Roberton, Andrew, Burden, Eleanor, Nagi, Sameer, Johnson-Lynn, Sarah, Guiot, Luke, Kostusiak, Milosz, Appleyard, Thomas, Mundy, Gary, Basha, Amr, Abdeen, Bashar, Robertson-Smith, Bill, Hussainy, Haydar Al, Reed, Mike, Jamalfar, Aral, Flintoft, Emily, McGovern, Julia, Alcock, Liam, Koziara, Michal, Ollivere, Benjamin, Zheng, Amy, Atia, Fady, Goff, Thomas, Slade, Henry, Teoh, Kar, Shah, Nikhil, Al-Obaedi, Ossama, Jamal, Bilal, Bell, Stuart, Macey, Alistair, Brown, Cameron, Simpson, Cameron, Alho, Roberto, Wilson, Victoria, Lewis, Charlotte, Blyth, Daniel, Chapman, Laura, Woods, Lisa, Katmeh, Rateb, Pasapula, Chandra, Youssef, Hesham, Tan, Jerry, Famure, Steven, Grazette, Andrew, Lloyd, Adam, Beaven, Alastair, Jackowski, Anna, Piper, Dani, Lotfi, Naeil, Chakravarthy, Jagannath, Elzawahry, Ahmed, Trew, Christopher, Neo, Chryssa, Elamin-Ahmed, Hussam, Ashwood, Neil, Wembridge, Kevin, Eyre-Brook, Alistair, Greaves, Amy, Watts, Anna, Stedman, Tobias, Ker, Andrew, Wong, Li Siang, Fullarton, Mairi, Phelan, Sean, Choudry, Qaisar, Qureshi, Alham, Moulton, Lawrence, Cadwallader, Craig, Jenvey, Cara, Aqeel, Aqeel, Francis, Daniel, Simpson, Robin, Phillips, Jon, Matthews, Edward, Thomas, Ellen, Williams, Mark, Jones, Robin, White, Tim, Ketchen, Debbie, Bell, Katrina, Swain, Keri, Chitre, Amol, Lum, Joann, Syam, Kevin, Dupley, Leanne, O'Brien, Sarah, Ford, David, Chapman, Taya, Zahra, Wajiha, Guryel, Enis, McLean, Elizabeth, Dhaliwal, Kawaljit, Regan, Nora, Berstock, James, Deano, Krisna, Donovan, Richard, Blythe, Andrew, Salmon, Jennifer, Craig, Julie, Hickland, Patrick, Matthews, Scott, Brown, William, Borland, Steven, Aminat, Akinsemoyin, Stamp, Gregory, Zaheen, Humayoon, Jaibaji, Monketh, Egglestone, Anthony, Sampalli, Sridhar Rao, Goodier, Henry, Gibb, Julia, Islam, Saad, Ranaboldo, Tom, Theivendran, Kanthan, Bond, Georgina, Richards, Joanna, Sanghera, Ranjodh, Robinson, Karen, Fong, Angus, Tsang, Bonita, Dalgleish, James, McGregor-Riley, Jonathan, Barkley, Sarah, Eardley, William, Elhassan, Almutasim, Tyas, Ben, Chandler, Henry, McVie, James, Wei, Nicholas, Negus, Oliver, Baldock, Thomas, Ravi, Kuppuswamy, Qazzaz, Layth, Mohamed, Muawia, Sivayoganthan, Sriharan, Poole, William, Slade, George, Beaumont, Hugo, Beaumont, Oliver, Taha, Rowa, Lever, Caroline, Sood, Abhay, Moss, Maximillian, Khatir, Mohammed, Trompeter, Alex, Jeffers, Aisha, Brookes, Charlotte, Dadabhoy, Maria, Bhattacharya, Rajarshi, Singh, Abhinav, Beer, Alexander, Hodgson, Harry, Rahman, Kashed, Barter, Reece, Mackinnon, Thomas, Frasquet-Garcia, Antonio, Aldarragi, Ameer, Warner, Christian, Pantelides, Christopher, Attwood, Joseph, Al-Uzri, Muntadhir, Qaoud, Qaiys Abu, Green, Stephen, Osborne, Alex, Griffiths, Alexandra, Emmerson, Benjamin, Slater, Duncan, Altahoo, Hasan, Scott, Helen, Rowland, David, O'Donnell, Janine, Edwards, Taff, Hafez, Ahmed, Khan, Basharat, Crane, Emily, Axenciuc, Rostislav, Al-Habsi, Ruqaiya, McAlinden, Gavan, Sterne, Jonathan, Wong, Matthew Lynch, Patil, Sunit, Ridha, Ali, Rasidovic, Damir, Searle, Henry, Choudhry, Jamaal, Farhan-Alanie, Muhamed M, Tanagho, Andy, Sharma, Sidharth, Thomas, Suresh, Smith, Ben, McMullan, Mark, Winstanley, Robert, Mirza, Saqeb, Hamlin, Katharine, Elgayar, Lugman, Larsen, Matthew P, Eissa, Mohamed, Stevens, Samuel, Hopper, Graeme P, Fang Soh, Terrence Chi, Doorgakant, Ashtin, Yogeswaran, Apimaan, Myatt, Darren, Mahon, Joseph, Ward, Nicholas, Reid, Susan, Deierl, Krisztian, Brogan, Declan, Little, Max, Deakin, Sue, Baines, Elliott, Jones, Georgie, Boulton, Helen, Douglas, Trixie, Jeyaseelan, Lucky, Abdale, Abdirizak, Islam, Aminul, Atkinson, Kate V, Mohamedfaris, Khalid, Mmerem, Kingsley, Jamal, Shazil, Wharton, Danielle, Rana, Anurag, McAllister, Ross, Sasi, Sijith, Thomas, Terin, Pillai, Anand, Flaherty, David, Khan, Munir, Akkena, Sudheer, Shandala, Yaseen, Lankester, Benedict, Hainsworth, Louis, Ahmed, Hussam Elamin, Walshaw, Thomas, Walker, Reece, and Eardley, William G.P.

Published
2023
Full Text
View/download PDF

39. Challenges and practical considerations in the management of blastic plasmacytoid dendritic cell neoplasm: A single-center experience

Author

Haripriya Andanamala, Naveen Pemmaraju, and Taha Al-Juhaishi

Subjects
BPDCN, Stem cell transplantation, Targeted therapy, Rare cancers, Case series, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and often life-threatening complex hematologic malignancy that can commonly infiltrate the skin, lymph nodes, central nervous system, and bone marrow. In the setting of the infrequency of confirmed diagnoses of BPDCN, and given limited prospective studies, it has been associated with lackluster outcomes with a median overall survival between 9 and 23 months. We herein discuss our experience treating five consecutive patients with BPDCN at our center since the approval of TAG. We also present some of the challenges that face oncology providers treating this disease due to exceptional rarity and aggressive nature of this disease in addition to overall limited experience and effective therapies

Published
2024
Full Text
View/download PDF

40. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia

Author

Senapati, Jayastu, Urrutia, Samuel, Loghavi, Sanam, Short, Nicholas J., Issa, Ghayas C., Maiti, Abhishek, Abbas, Hussein A., Daver, Naval G., Pemmaraju, Naveen, Pierce, Sherry, Chien, Kelly S., Sasaki, Koji, Kadia, Tapan M., Hammond, Danielle E., Borthakur, Gautam, Patel, Keyur, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, and DiNardo, Courtney D.

Published
2023
Full Text
View/download PDF

41. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells

Author

Carter, Bing Z., Mak, Po Yee, Muftuoglu, Muharrem, Tao, Wenjing, Ke, Baozhen, Pei, Jingqi, Bedoy, Andrea D., Ostermann, Lauren B., Nishida, Yuki, Isgandarova, Sevinj, Sobieski, Mary, Nguyen, Nghi, Powell, Reid T., Martinez-Moczygemba, Margarita, Stephan, Clifford, Basyal, Mahesh, Pemmaraju, Naveen, Boettcher, Steffen, Ebert, Benjamin L., Shpall, Elizabeth J., Wallner, Barbara, Morgan, Robert A., Karras, Georgios I., Moll, Ute M., and Andreeff, Michael

Published
2023
Full Text
View/download PDF

42. First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

Author

Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, William Donnellan, Lucille Ferrante, Jenna D. Goldberg, Michael R. Grunwald, Christina Guttke, Xiang Li, Jose Antonio Perez‐Simon, Olga Salamero, Trevor Tucker, Xiaoying Xu, Jay Yang, Naveen Pemmaraju, and Juan Manuel Alonso‐Dominguez

Subjects
Therapeutics. Pharmacology, RM1-950, Public aspects of medicine, RA1-1270
Abstract

Abstract This study aimed to identify a recommended phase II dose and evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary clinical activity of JNJ‐63709178, a CD123/CD3 dual‐targeting antibody, in patients with relapsed or refractory acute myeloid leukemia. Intravenous (i.v.) and subcutaneous (s.c.) administration of JNJ‐63709178 were evaluated. The i.v. infusions were administered once every 2 weeks (cohorts 1–5 [n = 17]) or twice weekly (cohorts 6–11 [n = 36]). A twice‐weekly s.c. dosing regimen with step‐up dosing was also studied (s.c. cohorts 1–2 [n = 9]). Treatment‐emergent adverse events (TEAEs) greater than or equal to grade 3 were observed in 11 (65%) patients in cohorts 1–5 and 33 (92%) patients in cohorts 6–11. At the highest i.v. dose (4.8 μg/kg), 5 (71%) patients discontinued treatment due to TEAEs. For s.c. administration (n = 9), eight (89%) patients experienced TEAEs greater than or equal to grade 3 and injection site reactions (≤ grade 3) emerged in all patients. At 4.8 μg/kg (i.v. and s.c.), the mean maximum serum concentrations were 30.3 and 3.59 ng/ml, respectively. Increases in multiple cytokines were observed following i.v. and s.c. administrations, and step‐up dosing strategies did not mitigate cytokine production or improve the safety profile and led to limited duration of treatment. Minimal clinical activity was observed across all cohorts. The i.v. and s.c. dosing of JNJ‐63709178 was associated with suboptimal drug exposure, unfavorable safety profiles, limited clinical activity, and inability to identify a recommended phase II dose.

Published
2023
Full Text
View/download PDF

43. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Author

Yap, Timothy A., Daver, Naval, Mahendra, Mikhila, Zhang, Jixiang, Kamiya-Matsuoka, Carlos, Meric-Bernstam, Funda, Kantarjian, Hagop M., Ravandi, Farhad, Collins, Meghan E., Francesco, Maria Emilia Di, Dumbrava, Ecaterina E., Fu, Siqing, Gao, Sisi, Gay, Jason P., Gera, Sonal, Han, Jing, Hong, David S., Jabbour, Elias J., Ju, Zhenlin, Karp, Daniel D., Lodi, Alessia, Molina, Jennifer R., Baran, Natalia, Naing, Aung, Ohanian, Maro, Pant, Shubham, Pemmaraju, Naveen, Bose, Prithviraj, Piha-Paul, Sarina A., Rodon, Jordi, Salguero, Carolina, Sasaki, Koji, Singh, Anand K., Subbiah, Vivek, Tsimberidou, Apostolia M., Xu, Quanyun A., Yilmaz, Musa, Zhang, Qi, Li, Yuan, Bristow, Christopher A., Bhattacharjee, Meenakshi B., Tiziani, Stefano, Heffernan, Timothy P., Vellano, Christopher P., Jones, Philip, Heijnen, Cobi J., Kavelaars, Annemieke, Marszalek, Joseph R., and Konopleva, Marina

Published
2023
Full Text
View/download PDF

45. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

Author

Jabbour, Elias, Short, Nicholas J, Senapati, Jayastu, Jain, Nitin, Huang, Xuelin, Daver, Naval, DiNardo, Courtney D, Pemmaraju, Naveen, Wierda, William, Garcia-Manero, Guillermo, Montalban Bravo, Guillermo, Sasaki, Koji, Kadia, Tapan M, Khoury, Joseph, Wang, Sa A, Haddad, Fadi G, Jacob, Jovitta, Garris, Rebecca, Ravandi, Farhad, and Kantarjian, Hagop M

Published
2023
Full Text
View/download PDF

46. ORthopaedic trauma hospital outcomes - Patient operative delays (ORTHOPOD) Study: The management of day-case orthopaedic trauma in the United Kingdom

Author

Stevenson, Iain, Yoong, Andrel, Rankin, Iain, Dixon, James, Lim, Jun Wei, Sattar, Mariam, McDonald, Stephen, Scott, Sharon, Davies, Helen, Jones, Louise, Nolan, Michelle, McGinty, Rebecca, Stevenson, Helene, Bowe, David, Sim, Francis, Vun, James, Strain, Ritchie, Giannoudis, Vasileios, Talbot, Christopher, Gunn, Christopher, Le, Ha Phuong Do, Bradley, Matthew, Lloyd, William, Hanratty, Brian, Lim, Yizhe, Brookes-Fazakerley, Steven, Varasteh, Amir, Francis, Jonathan, Choudhry, Nameer, Malik, Sheraz, Vats, Amit, Evans, Ashish, Garner, Madeleine, King, Stratton, Zbaeda, Mohamed, Diamond, Owen, Baker, Gavin, Napier, Richard, Guy, Stephen, McCauley, Gordon, King, Samuel, Edwards, Gray, Lin, Benjamin, Davoudi, Kaveh, Haines, Samuel, Raghuvanshi, Manav, Buddhdev, Pranai, Karam, Edward, Nimmyel, Enoch, Ekanem, George, Lateef, Razaq, Jayadeep, JS, Crowther, Ian, Mazur, Karolina, Hafiz, Nauman, Khan, Umair, Chettiar, Krissen, Ibrahim, Amr, Gopal, Prasanth, Tse, Shannon, Lakshmipathy, Raj, Towse, Claudia, Al-Musawi, Hashim, Walmsley, Matthew, Aspinall, Will, Metcalfe, James, Moosa, Aliabbas, Crome, George, Abdelmonem, Mohamed, Lakpriya, Sathya, Hawkins, Amanda, Waugh, Dominic, Kennedy, Matthew, Elsagheir, Mohamed, Kieffer, Will, Oyekan, Adekinte, Collis, Justin, Raad, Marjan, Raut, Pramin, Baker, Markus, Gorvett, Alexander, Gleeson, Hannah, Fahmy, John, Walters, Sam, Tinning, Craig, Chaturvedi, Abhishek, Russell, Heather, Alsawada, Osama, Sinnerton, Robert, Crane, Evan, Warwick, Catherine, Dimascio, Lucia, Ha, Taegyeong Tina, King, Thomas, Engelke, Daniel, Chan, Matthew, Gopireddy, Rajesh, Deo, Sunny, Vasarhelyi, Ferenc, Jhaj, Jasmeet, Dogramatzis, Kostas, McCartney, Sarah, Ardolino, Toni, Fraig, Hossam, Hiller-Smith, Ryan, Haughton, Benjamin, Greenwood, Heather, Stephenson, Nicola, Chong, Yuki, Sleat, Graham, Saedi, Farid, Gouda, Joe, Ravi, Sanjeev Musuvathy, Henari, Shwan, Imam, Sam, Howell, Charles, Theobald, Emma, Wright, Jan, Cormack, Jonathan, Borja, Karlou, Wood, Sandy, Khatri, Amulya, Bretherton, Chris, Tunstall, Charlotte, Lowery, Kathryn, Holmes, Benjamin, Nichols, Jennifer, Bashabayev, Beibit, Wildin, Clare, Sofat, Rajesh, Thiagarajan, Aarthi, Abdelghafour, Karim, Nicholl, James, Abdulhameed, Ahmed, Duke, Kathryn, Maling, Lucy, McCann, Matthew, Masud, Saqib, Marshman, James, Moreau, Joshua, Cheema, Kanwalnaini, Rageeb, Peter Morad, Mirza, Yusuf, Kelly, Andrew, Hassan, Abdul, Christie, Alexander, Davies, Angharad, Tang, Cary, Frostick, Rhiannon, Pemmaraju, Gopalakrishna, Handford, Charles, Chauhan, Govind, Dong, Huan, Choudri, Mohammed Junaid, Loveday, David, Bawa, Akshdeep, Baldwick, Cheryl, Roberton, Andrew, Burden, Eleanor, Nagi, Sameer, Johnson-Lynn, Sarah, Guiot, Luke, Kostusiak, Milosz, Appleyard, Thomas, Mundy, Gary, Basha, Amr, Abdeen, Bashar, Robertson-Smith, Bill, Hussainy, Haydar Al, Reed, Mike, Jamalfar, Aral, Flintoft, Emily, McGovern, Julia, Alcock, Liam, Koziara, Michal, Ollivere, Benjamin, Zheng, Amy, Atia, Fady, Goff, Thomas, Slade, Henry, Teoh, Kar, Shah, Nikhil, Al-Obaedi, Ossama, Jamal, Bilal, Bell, Stuart, Macey, Alistair, Brown, Cameron, Simpson, Cameron, Alho, Roberto, Wilson, Victoria, Lewis, Charlotte, Blyth, Daniel, Chapman, Laura, Woods, Lisa, Katmeh, Rateb, Pasapula, Chandra, Youssef, Hesham, Tan, Jerry, Famure, Steven, Grazette, Andrew, Lloyd, Adam, Beaven, Alastair, Jackowski, Anna, Piper, Dani, Lotfi, Naeil, Chakravarthy, Jagannath, Elzawahry, Ahmed, Trew, Christopher, Neo, Chryssa, Elamin-Ahmed, Hussam, Ashwood, Neil, Wembridge, Kevin, Eyre-Brook, Alistair, Greaves, Amy, Watts, Anna, Stedman, Tobias, Ker, Andrew, Wong, Li Siang, Fullarton, Mairi, Phelan, Sean, Choudry, Qaisar, Qureshi, Alham, Moulton, Lawrence, Cadwallader, Craig, Jenvey, Cara, Aqeel, Aqeel, Francis, Daniel, Simpson, Robin, Phillips, Jon, Matthews, Edward, Thomas, Ellen, Williams, Mark, Jones, Robin, White, Tim, Ketchen, Debbie, Bell, Katrina, Swain, Keri, Chitre, Amol, Lum, Joann, Syam, Kevin, Dupley, Leanne, O'Brien, Sarah, Ford, David, Chapman, Taya, Zahra, Wajiha, Guryel, Enis, McLean, Elizabeth, Dhaliwal, Kawaljit, Regan, Nora, Berstock, James, Deano, Krisna, Donovan, Richard, Blythe, Andrew, Salmon, Jennifer, Craig, Julie, Hickland, Patrick, Matthews, Scott, Brown, William, Borland, Steven, Aminat, Akinsemoyin, Stamp, Gregory, Zaheen, Humayoon, Jaibaji, Monketh, Egglestone, Anthony, Sampalli, Sridhar Rao, Goodier, Henry, Gibb, Julia, Islam, Saad, Ranaboldo, Tom, Theivendran, Kanthan, Bond, Georgina, Richards, Joanna, Sanghera, Ranjodh, Robinson, Karen, Fong, Angus, Tsang, Bonita, Dalgleish, James, McGregor-Riley, Jonathan, Barkley, Sarah, Eardley, William, Elhassan, Almutasim, Tyas, Ben, Chandler, Henry, McVie, James, Wei, Nicholas, Negus, Oliver, Baldock, Thomas, Ravi, Kuppuswamy, Qazzaz, Layth, Mohamed, Muawia, Sivayoganthan, Sriharan, Poole, William, Slade, George, Beaumont, Hugo, Beaumont, Oliver, Taha, Rowa, Lever, Caroline, Sood, Abhay, Moss, Maximillian, Khatir, Mohammed, Trompeter, Alex, Jeffers, Aisha, Brookes, Charlotte, Dadabhoy, Maria, Bhattacharya, Rajarshi, Singh, Abhinav, Beer, Alexander, Hodgson, Harry, Rahman, Kashed, Barter, Reece, Mackinnon, Thomas, Frasquet-Garcia, Antonio, Aldarragi, Ameer, Warner, Christian, Pantelides, Christopher, Attwood, Joseph, Al-Uzri, Muntadhir, Qaoud, Qaiys Abu, Green, Stephen, Osborne, Alex, Griffiths, Alexandra, Emmerson, Benjamin, Slater, Duncan, Altahoo, Hasan, Scott, Helen, Rowland, David, O'Donnell, Janine, Edwards, Taff, Hafez, Ahmed, Khan, Basharat, Crane, Emily, Axenciuc, Rostislav, Al-Habsi, Ruqaiya, McAlinden, Gavan, Sterne, Jonathan, Wong, Matthew Lynch, Patil, Sunit, Ridha, Ali, Rasidovic, Damir, Searle, Henry, Choudhry, Jamaal, Farhan-Alanie, Muhamed M, Tanagho, Andy, Sharma, Sidharth, Thomas, Suresh, Smith, Ben, McMullan, Mark, Winstanley, Robert, Mirza, Saqeb, Hamlin, Katharine, Elgayar, Lugman, Larsen, Matthew P, Eissa, Mohamed, Stevens, Samuel, Hopper, Graeme P, Fang Soh, Terrence Chi, Doorgakant, Ashtin, Yogeswaran, Apimaan, Myatt, Darren, Mahon, Joseph, Ward, Nicholas, Reid, Susan, Deierl, Krisztian, Brogan, Declan, Little, Max, Deakin, Sue, Baines, Elliott, Jones, Georgie, Boulton, Helen, Douglas, Trixie, Jeyaseelan, Lucky, Abdale, Abdirizak, Islam, Aminul, Atkinson, Kate V, Mohamedfaris, Khalid, Mmerem, Kingsley, Jamal, Shazil, Wharton, Danielle, Rana, Anurag, McAllister, Ross, Sasi, Sijith, Thomas, Terin, Pillai, Anand, Flaherty, David, Khan, Munir, Akkena, Sudheer, Shandala, Yaseen, Lankester, Benedict, Hainsworth, Louis, Baldock, Thomas E., Walshaw, Thomas, Walker, Reece, and Eardley, William P.G.

Published
2023
Full Text
View/download PDF

48. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Author

Jain, Nitin, Senapati, Jayastu, Thakral, Beenu, Ferrajoli, Alessandra, Thompson, Philip, Burger, Jan, Basu, Sreyashi, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Konopleva, Marina, Pemmaraju, Naveen, Parry, Erin, Wu, Catherine J., Khoury, Joseph, Bueso-Ramos, Carlos, Garg, Naveen, Wang, Xuemei, Lopez, Wanda, Ayala, Ana, O’Brien, Susan, Kantarjian, Hagop, Keating, Michael, Allison, James, Sharma, Padmanee, and Wierda, William

Published
2023
Full Text
View/download PDF

50. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Author

Issa, Ghayas C., Bidikian, Aram, Venugopal, Sangeetha, Konopleva, Marina, DiNardo, Courtney D., Kadia, Tapan M., Borthakur, Gautam, Jabbour, Elias, Pemmaraju, Naveen, Yilmaz, Musa, Short, Nicholas J., Maiti, Abhishek, Sasaki, Koji, Masarova, Lucia, Pierce, Sherry, Takahashi, Koichi, Tang, Guilin, Loghavi, Sanam, Patel, Keyur, Andreeff, Michael, Bhalla, Kapil, Garcia-Manero, Guillermo, Ravandi, Farhad, Kantarjian, Hagop, and Daver, Naval

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results